BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
12% short interest
Very Volatile but high risk high reward.
Average analysts price target $8.043 | Overweight
12% short interest
Very Volatile but high risk high reward.
Average analysts price target $8.043 | Overweight